Sangamo Therapeutics Inc
NASDAQ:SGMO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Sangamo Therapeutics Inc
NASDAQ:SGMO
|
US |
|
Fidea Holdings Co Ltd
TSE:8713
|
JP |
|
Recon Technology Ltd
NASDAQ:RCON
|
CN |
|
Reclaims Global Ltd
SGX:NEX
|
SG |
|
Appfolio Inc
NASDAQ:APPF
|
US |
|
F
|
Fox Wizel Ltd
TASE:FOX
|
IL |
|
Amylyx Pharmaceuticals Inc
NASDAQ:AMLX
|
US |
|
ARE Holdings Inc
F:A19
|
JP |
|
F
|
Forterra Inc
F:05G
|
US |
|
S
|
SUMBER ENERGI ANDALAN Tbk PT
IDX:ITMA
|
ID |
|
B
|
Babcock International Group PLC
OTC:BCKIY
|
UK |
|
Eucatex SA Industria e Comercio
BOVESPA:EUCA4
|
BR |
|
H
|
Hunter Douglas NV
F:HUD
|
NL |
|
L
|
Lycos Energy Inc
XTSX:LCX
|
CA |
|
Essential Metals Ltd
ASX:ESS
|
AU |
|
Chubb Ltd
NYSE:CB
|
CH |
|
Mazda Ltd
NSE:MAZDA
|
IN |
|
Reading International Inc
NASDAQ:RDI
|
US |
|
Acrow Formwork and Construction Services Ltd
ASX:ACF
|
AU |
|
M
|
Mercurius Capital Investment Ltd
SGX:5RF
|
SG |
|
G
|
Greenhill & Co Inc
F:GH3
|
US |
|
5
|
51Talk Online Education Group
AMEX:COE
|
SG |
|
Joyce Corporation Ltd
ASX:JYC
|
AU |
|
TP Group PLC
LSE:TPG
|
UK |
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is SGMO's stock price target?
Not Available
SGMO doesn't have any price targets made by Wall Street professionals.
What is Sangamo Therapeutics Inc's Revenue forecast?
Projected CAGR
38%
For the last 13 years the
compound annual growth rate for
Sangamo Therapeutics Inc's revenue is
14%.
The projected
CAGR
for the next 4 years is
38%.